Antiresorptive effects of single zoledronate dose are sustained for 3 years
Prolonged antiresorptive activity of zoledronate: a randomized, controlled trialJ Bone Miner Res. 2010 Oct;25(10):2251-5
Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
50 postmenopausal women with osteopenia were randomized to receive either a single 5 mg dose of intravenous zoledronate or a placebo to determine the duration of antiresorptive action. Patients were assessed for bone turnover markers b-C-terminal telopeptide of type I collagen (b-CTX) and serum procollagen type-I N-terminal propeptide (P1NP). They were also assessed for bone mineral density (BMD) ...
Learn about our AI Driven
High Impact Search Feature
Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.Continue